|
|
|
|
|
|
|
|
Abstract
Highlights
- •
- Using personal protection equipment, administration of intraperitoneal cisplatin during optimal debulking surgery is safe to involved healthcare personnel.
- •
- This is the first report of its kind to evaluate the safety of healthcare personnel during debulking surgery.
Ovarian
cancer is the leading cause of death from gynecologic malignancies in
the United States. In 2006, the National Cancer Institute released an
announcement supporting the use of intraperitoneal (IP) chemotherapy in
advanced ovarian cancer. It remains unanswered how many cycles of IP
chemotherapy are required to maintain a survival advantage. There may be
a benefit with as few as three IP cycles and possibly as few as one IP
chemotherapy cycle.
Objective
In
preparation for a clinical trial in which chemotherapy would be
administered intra-operatively, the question of exposure to healthcare
personnel arose, therefore, the purpose of this study was to perform an
evaluation of healthcare personnel exposure to cisplatin during a mock
demonstration of intraperitoneal chemotherapy administration.
Materials and methods
The
National Institute of Occupational Safety and Health (NIOSH), the
Women's Cancer Center of Nevada, and the staff of the University Medical
Center, Las Vegas, participated in this mock demonstration. Employees
wore personal protective equipment recommended by NIOSH. Wipe, area, and
breathing zone air samples were taken from the pharmacy and operating
room, and during sterilization of equipment.
Results
All
samples were negative for cisplatin, except for one surface wipe from
the floor of the operating room (OR) after the mock procedure. Upon
sanitization of the OR, no cisplatin was detected on the floor.
Conclusion
This
was the first study evaluating the exposure of healthcare personnel to
the administration of cisplatin intra-operatively. NIOSH endorsed this
practice so long as the employees adhere to using the recommended
personal protective equipment.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.